Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
Alexandra PenderEmma TitmussErin D PleasanceKevin Y FanHillary PearsonScott D BrownCameron J GrisdaleJames T TophamYaoqing ShenMelika BonakdarGregory A TaylorLaura M WilliamsonAndrew J MungallEric ChuahRichard A MooreJean-Michel LavoieStephen YipHoward LimDaniel J RenoufSophie SunRobert A HoltSteven J M JonesMarco A MarraJanessa LaskinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Interpreting the tumor-immune interface to predict ICI efficacy remains challenging. WGTA allows for identification of multiple biomarkers simultaneously that in combination may help to identify responders, particularly in the context of a heterogeneous population of advanced and previously treated cancers, thus precluding tumor type-specific testing.